H And H Pharmaceutica Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 7.50 M
as on 16-11-2024
- Company Age 28 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 4.50 M
as on 16-11-2024
- Revenue -70.04%
(FY 2023)
- Profit -29.47%
(FY 2023)
- Ebitda 22.08%
(FY 2023)
- Net Worth 0.22%
(FY 2023)
- Total Assets 0.09%
(FY 2023)
About H And H Pharmaceutica
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.50 M.
The company has closed loans amounting to ₹4.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anaita Hegde, Mrinalini Hegde, and Hemanth Hegde serve as directors at the Company.
- CIN/LLPIN
U24230MH1996PTC098684
- Company No.
098684
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Apr 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at H And H Pharmaceutica?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anaita Hegde  | Director | 08-Apr-1996 | Current |
| Mrinalini Hegde | Director | 08-Apr-1996 | Current |
| Hemanth Hegde | Director | 08-Apr-1996 | Current |
Financial Performance of H And H Pharmaceutica.
H And H Pharmaceutica Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 70.04% decrease. The company also saw a substantial fall in profitability, with a 29.47% decrease in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of H And H Pharmaceutica?
In 2023, H And H Pharmaceutica had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Hegde & Hegde Pharmaceutica LlpActive 11 years 8 months
Anaita Hegde and Hemanth Hegde are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vijaya Bank Creation Date: 17 Jun 1998 | ₹2.50 M | Satisfied |
Vijaya Bank Creation Date: 24 Aug 1996 | ₹2.00 M | Satisfied |
How Many Employees Work at H And H Pharmaceutica?
Unlock and access historical data on people associated with H And H Pharmaceutica, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of H And H Pharmaceutica, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped H And H Pharmaceutica's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
